Safety and Efficacy of 2D Brachytherapy vs. 3D Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer—A Single Institution Retrospective Study
Current Oncology · 13.05.2023 · 30 (5) · 4966-4978
DOI: 10.3390/curroncol30050375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 13.05.2023. Verfasst von Mame Daro Faye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Brachytherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The treatment paradigm for locally advanced cervical cancer (LACC) has shifted from two-dimensional-brachytherapy (2D-BT) to three-dimensional-image-guided adaptive BT (3D-IGABT). In this retrospective study, we report our experience with the change from 2D-BT to 3D-IGABT.
Methods
We reviewed 146 LACC patients (98 3D-IGABT and 48 2D-BT) who received chemoradiation between 2004 and 2019. The multivariable odds ratio (OR) for treatment-related toxicities and hazard ratios (HR) for locoregional control (LRC), distant control (DC), failure-free survival (FFS), cancer-specific survival (CSS) and overall survival (OS) are reported.
Results
The median follow-up was 50.3 months. There was a significant decrease in overall late toxicities in the 3D-IGABT group compared to the 2D-BT group (OR 0.22[0.10–0.52]), late gastrointestinal (OR 0.31[0.10–0.93]), genitourinary (OR 0.31[0.09–1.01]) and vaginal toxicities (0% vs. 29.6%). Grade ≥ 3 toxicity was low in both groups (2D-BT: 8.2% acute, 13.3% late vs. 3D-IGABT: 6.3% acute, 4.4% late, NS). The five-year LRC, DC, FFS, CSS and OS for 3D-IGABT were 92.0%, 63.4%, 61.7%, 75.4% and 73.6%, compared to 87.3%, 71.8%, 63.7%, 76.3% and 70.8% for 2D-BT (NS).
Conclusions
3D-IGABT for the treatment of LACC is associated with a decrease in overall late gastrointestinal, genitourinary and vaginal toxicities. The disease control or survival outcomes were comparable to contemporary 3D-IGABT studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Radiation Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
- Division of Cancer Epidemiology, Oncology, McGill University, Montreal, QC H4A 3T2, Canada.
- Department of Gynecology-Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
ORCID-Profile: Mame Daro Faye, Lucy Gilbert, Joanne Alfieri
Zitieren
APA
Faye, M. D., Petruccelli Araujo, M., Wissing, M. D., Alrabiah, K., Gilbert, L., Zeng, X., Souhami, L., & Alfieri, J. (2023). Safety and Efficacy of 2D Brachytherapy vs. 3D Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer—A Single Institution Retrospective Study. Current Oncology, 30(5), 4966-4978. https://doi.org/10.3390/curroncol30050375
Vancouver
Faye MD, Petruccelli Araujo M, Wissing MD, Alrabiah K, Gilbert L, Zeng X, et al. Safety and Efficacy of 2D Brachytherapy vs. 3D Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer—A Single Institution Retrospective Study. Current Oncology. 2023;30(5):4966-4978. doi:10.3390/curroncol30050375
BibTeX
@article{Faye2023,
author = {Faye, Mame Daro and Petruccelli Araujo, Mariana and Wissing, Michel D and Alrabiah, Khalid and Gilbert, Lucy and Zeng, Xing and Souhami, Luis and Alfieri, Joanne},
title = {Safety and Efficacy of 2D Brachytherapy vs. 3D Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer—A Single Institution Retrospective Study},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {5},
pages = {4966--4978},
doi = {10.3390/curroncol30050375}
}
EUVIMED